A Retrospective Study Concerning Drug Utilization Evaluation in COVID- 19 Patients | Chapter 6 | Research Developments in Medicine and Medical Science Vol. 1

 Corona affliction 2019 (COVID-19) is an airborne zealous infectious disease led to by severe severe respiratory condition coronavirus 2 (SARS-CoV-2) mutants. Transmission can occur if adulterated fluids are splashed or sprayed into the eyes, nose, or backtalk, or, in rare cases, through adulterated surfaces. The standard diagnostic plan and treatment pattern varies from clinic to hospital, that provokes completing activity this work.The study aims to assess the drug situation pattern, antibiotic usages patterns, and cost and determine the antiviral custom pattern and price. This retrospective practical study was conducted in Sagar Hospitals, Kumaraswamy Layout, Bangalore, for six months later obtaining ethical approval using a well-planned questionnaire. The healing records department given 155 cases. The findings showed that Ceftriaxone, a container wall combining inhibitor, was ultimate commonly used medicine (60.6%), followed by Azithromycin, a protein combination inhibitor (59.4%). Oseltamivir was ultimate commonly secondhand antiviral in 51.6% of patients, Remdesivir in 41.3%, and Favipiravir in 12.3%. Other co-morbid drugs are corticosteroids, immunomodulators, mucolytics, antihistamines, ancestry thinners, and anti-helminthes. The mean cost of the medicines and antiviral are 224 ± 295.73; 1623.28 ± 2047.45.This study demonstrated that the ICMR Guidelines were understood in the management of COVID-19. The cost of the medications, specifically antibiotics, antivirals, and immunomodulators, had a substantial impact on the situation regimens preferred. Therefore, cost consideration studies may aid in advancing rational cure use and reducing costs guide disease management.

Author(s) Details:

K. V. Ramanath,
Suryadatta College of Pharmacy Health Care and Research Centere (SCPHR), Pune & Department of Pharmacy Practice, Dayananda Sagar University, India.

Sharvari Venugopal,
Dayananda Sagar University, India.

A. Shadakshari,
Dayananda Sagar University, India.

B. Abinavi,
Dayananda Sagar University, India.

Harsharan Kaur,
Dayananda Sagar University, India.

Leeba Jacob,
Sagar Hospitals, Bangalore, India.

Please see the link here: https://stm.bookpi.org/RDMMS-V1/article/view/9623